AI-Driven Analysis Optimizes Clinical Strategy for A28’s Liver Cancer Peptide Therapy

A28 Therapeutics, a clinical-stage biopharmaceutical company, and GATC Health Corp, a developer of AI-driven drug discovery tools, have announced the …

Continue ›››

Umoja Secures $100M For In Vivo CAR-T Therapies

Umoja Biopharma has secured $100 million in an oversubscribed Series C funding round. Based in Seattle, Washington, and founded in …

Continue ›››

Eli Lilly Acquires Scorpion Therapeutics' Oncology Program for $2.5 Billion

Eli Lilly announced the acquisition of Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program for up to $2.5 billion, expanding its oncology …

Continue ›››

Vevo Therapeutics Plans to Open Source 100M Single-Cell Atlas for Drug Discovery

Vevo Therapeutics has announced plans to open source its Tahoe-100M dataset, described as the world's largest single-cell transcriptomic atlas of …

Continue ›››

Bioptimus Reaches $76M Milestone as It Prepares for Next-Gen AI Foundation Model

Bioptimus, a French AI startup, has announced a $76 million funding milestone, with $41 million secured in its latest round …

Continue ›››

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera has announced an expansion of its collaboration with AbbVie to include the development of T-cell engagers (TCEs) for oncology, …

Continue ›››

AbbVie Partners with Simcere on T-Cell Engager for Multiple Myeloma in $1B Deal

AbbVie has partnered with Simcere Zaiming, a subsidiary of Simcere Pharmaceutical, to advance a trispecific antibody candidate, SIM0500, for relapsed …

Continue ›››

Truveta Raises $320M to Sequence 10M Exomes and Build Largest Genetic Database

The health data company Truveta, in collaboration with Regeneron and Illumina, and 17 major U.S. health systems, has launched the …

Continue ›››

Gilead Strikes $1.7B Deal with LEO Pharma for Oral STAT6 Therapies in Inflammatory Diseases

Gilead Sciences has announced a $1.7 billion collaboration with LEO Pharma, expanding its portfolio beyond infectious diseases and into inflammatory …

Continue ›››

Bayer's Cell Therapy for Replacing Dopamine Neurons in Parkinson’s Advances to Phase III

Bayer, through its subsidiary BlueRock Therapeutics, has announced plans to advance bemdaneprocel (BRT-DA01), its investigational pluripotent stem cell-derived dopaminergic neuron therapy …

Continue ›››

Merck Partners with Atropos Health to Accelerate Real-World Evidence Generation

Atropos Health has announced a collaboration with Merck to utilize its suite of tools for real-world evidence (RWE) generation, including …

Continue ›››

Sana Reports Promising Results for Type 1 Diabetes Islet Cell Transplants Without Immunosuppression

Sana Biotechnology announced promising early results from a first-in-human study of its hypoimmune (HIP) technology for type 1 diabetes. Conducted …

Continue ›››